MDGL Stock Analysis: Buy, Sell, or Hold?
MDGL - Madrigal Pharmaceuticals, Inc. Common Stock
$516.74
-2.35 (-0.45%)
âŧ
5d:
+1.81%
30d:
-4.9%
90d:
+0.61%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When MDGL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: MDGL is fairly priced but lacks strong directional signals. At -17.9% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: MDGL is fairly priced but lacks strong directional signals. At -17.9% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$337.16
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$209.35
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: MDGL is currently trading at $516.74, which is considered fair relative to its 30-day fair value range of $504.31 to $546.90. From a valuation perspective, the stock is trading at a discount (Forward PE: 53.7) compared to its historical average (97.1). Remarkably, the market is currently pricing in an annual earnings decline of 17.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, MDGL is showing sideways momentum. Immediate support is located at $494.90, while resistance sits at $544.49.
Market Sentiment: The stock scores a mixed 49/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $678.06 (+31.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MDGL is showing sideways momentum. Immediate support is located at $494.90, while resistance sits at $544.49.
Market Sentiment: The stock scores a mixed 49/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $678.06 (+31.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$504.31 -
$546.90
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.7%
Protect Your Profits
Holding MDGL? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (49/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 31.2% below Wall St target ($678.06)
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$504.31 -
$546.90
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$28.59
(5.5%)
Support & Resistance Levels
Support Level
$494.90
Resistance Level
$544.49
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
53.69
Wall Street Target
$678.06
(+31.2%)
Revenue Growth (YoY)
71.2%
Profit Margin
-25.3%
Valuation Discount vs History
-17.9% cheaper
PE vs Historical
53.7 vs 97.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-17.9%
(market-implied from PE analysis)
1-Year Target
$465.07
(-10%)
2-Year Target
$418.56
(-19%)
3-Year Target
$376.70
(-27%)
3-Yr Target (if PE normalizes)
(PE: 54â97)
$681.31
(+32%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 53.7 to 97.1
Stabilization Target:
$934.59
(+80.9%)
PE Expansion Potential:
+80.9%
Share & Embed Analysis
Last updated: August 22, 2026 9:11 PM ET
Data refreshes hourly during market hours. Next update: 10:11 PM
Data refreshes hourly during market hours. Next update: 10:11 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MDGL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Mardi Dier
SELL
1982 shares
2026-03-06
Carole Huntsman
SELL
419 shares
2026-03-06
William John Sibold
SELL
1663 shares
2026-03-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 40 SELL |
|
EYPT
EyePoint, Inc |
STRONG BUY
13 analysts |
$41 | 44 HOLD |
Advanced MDGL Option Strategies
Professional options setups generated by AI based on today's MDGL price and gamma walls.
